Distinguished Prognosis of Hepatocellular Carcinoma with or Without Cirrhosis: A Long-term Follow-up Analysis

S. L. Yang,L. P. Liu,Y. F. Sun,X. R. Yang,J. Fan,J. W. Ren,G. G. Chen,P. B. S. Lai
DOI: https://doi.org/10.1016/j.cgh.2015.04.126
IF: 13.576
2015-01-01
Clinical Gastroenterology and Hepatology
Abstract:Conflicting results have been often observed in hepatocellular carcinoma (HCC) in prognosis analysis, but few studies attempt to explore the reasons for the conflicting results. We aimed to distinguish the prognosis of HCC with cirrhosis (HCC-C) and without (HCC-NC). Patients with HBV-associated HCC treated by curative liver resection at a single institution between 1995 and 2013 were retrospectively evaluated. Kaplan–Meier and multivariate analyses were performed to identify risk factors including tumor-related factors, hypoxia inducible factor (HIF)-1α, hepatitis B virus X protein (HBx) expression, and HBx double mutations for overall survival (OS) and disease-free survival (DFS) in these patients. The long-term prognosis for HCC-NC is better than HCC-C. Male, poor differentiation, preoperative serum alanine aminotransferase >80 IU/L and alpha fetoprotein >400 ng/ml were risk factors for OS among HCC-NC patients, but not HCC-C patients, and age >50 years was associated with a poor OS only in cirrhotic patients. HCC-C patients benefit more from antiviral therapy following curative hepatectomy compared with HCC-NC patients. Meanwhile, the clinical value of the biomarkers HIF-1α, HBx and HBx double mutations for predicting HCC prognosis was significantly different between these two groups. There was a difference in tumor-related prognostic factors, effect of antiviral therapy on the post-hepatectomy and biomarkers between these two subgroups, indicating that subgroup analysis of the prognostic factors may achieve better management of HCC and HCC patients especially combined with liver cirrhosis should be given antiviral therapy.
What problem does this paper attempt to address?